Abstract
Background
Postoperative prognosis for patients with pathologic (p-) stage IIIA-N2 non-small-cell lung cancer (NSCLC) is poor, and significant factors that influence the prognosis remain unclear.
Methods
A total of 99 patients who underwent complete resection for p-stage IIIA-N2 NSCLC without any preoperative therapy were retrospectively reviewed. Biological features such as tumor angiogenesis (intratumoral microvessel density [IMVD]), proliferative activity (proliferative index [PI]), and p53 status were also evaluated immunohistochemically.
Results
Univariate analysis revealed that the number of involved N2 stations was a significant prognostic factor; 5-year survival rates for a tumor with metastases in single N2 stations, tumor with metastases in two N2 stations, and tumor with metastases in 3 or more N2 stations were 41.6%, 35.3%, and 0.0%, respectively (P = .041) In addition, the 5-year survival rate for cN0-1 disease was significantly higher than that for cN2 disease (41.9% and 25.5%, respectively; P = .048) Tumor angiogenesis and proliferative activity were the most significant prognostic factors; 5-year survival rates for lower-IMDV tumor and higher-IMVD tumor were 53.6% and 15.9%, respectively (P = .002), and those for lower-PI tumor and higher-PI tumor were 47.0% and 20.4%, respectively (P = .019) There was no difference in the postoperative survival between tumor showing aberrant p53 expression and tumor showing no aberrant p53 expression. These results were confirmed by a multivariate analysis.
Conclusions
P-stage IIIA-N2 NSCLC cases represented a mixture of heterogeneous prognostic subgroups, and the number of involved N2 stations, cN status, PI, and IMVD were significant predictors of the survival.
Similar content being viewed by others
REFERENCES
Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;116:1710–7.
Tanaka F, Yanagihara K, Otake Y, et al. Surgery for non-small cell lung cancer: postoperative survival based on the revised tumor-node-metastasis classification and its time trend. Eur J Cardiothorac Surg 2000;18:147–55.
Vansteenkiste JF, De Leyn PR, Deneffe GJ, et al. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Ann Thorac Surg 1997;63:1441–50.
Okada M, Tsubota N, Yoshimura M, Miyamoto Y, Matsuoka H. Prognosis of completely resected pN2 non-small cell lung carcinomas: what is the significant node that affects survival?. J Thorac Cardiovasc Surg 1999;118:270–5.
Ichinose Y, Kato H, Koike T, et al. Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials. Lung Cancer 2001;34:29–36.
Pastorino U, Andreola S, Tagliabue E, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 1997;15:2858–65.
Angeletti CA, Lucchi M, Fontanini G, et al. Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (stage IIIA-N2). Cancer 1996;78:409–15.
Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. Prognostic significance of p53 alternations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 2000;6:4055–63.
Tanaka F, Otake Y, Yanagihara K, et al. Apoptosis and p53 status predict the efficacy of postoperative administration of UFT in non-small cell lung cancer. Br J Cancer 2001;84:263–9.
Tanaka F, Otake Y, Yanagihara K, et al. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 2001;7:3410–5.
American Society of Clinical Oncology. ASCO special article: Clinical practical guidelines for the treatment of unresectable non-small cell lung cancer. J Clin Oncol 1997;15:2996–3018.
Kumar S, Ghellal A, Li C, et al. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 1999;59:856–61.
Tanaka F, Yanagihara K, Otake Y, et al. Biological features and preoperative evaluation of mediastinal nodal status in non-small cell lung cancer. Ann Thorac Surg 2000;70:1832–8.
Travis WD, Colby TV, Shimosato, Corrin, Y, Brambilla E. World Health Organization International Histological Classification of Tumors: Histological Typing of Lung and Pleural Tumors. 3rd ed. Berlin: Springer, 1999.
Wada H, Hitomi S, Teramatsu T. West Japan Study Group for Lung Cancer Surgery. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. J Clin Oncol 1996;14:1048–54.
Wada H, Miyahara R, Tanaka F, Hitomi S. Postoperative adjuvant chemotherapy with PVM (cisplatin + vindesine + mitomycin C) and UFT (uracil + tegaful) in resected stage I-II NSCLC (non-small-cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJSG). Eur J Cardiothorac Surg 1999;15:438–43.
Tanaka F, Kawano Y, Li M, et al. Prognostic significance of apoptotic index in completely resected non-small cell lung cancer. J Clin Oncol 1999;17:2728–36.
Folkman J, Watson K, Ingiber D, Hanahan D. Induction of angiogenesis during transition from hyperplasia to neoplasia. Nature (Lond) 1989;339:58–61.
Harpole, Jr DH, Richards WG, Herndon II JE, Sugarbaker DJ. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann Thorac Surg 1996;61:1470–6.
Lucchi M, Fontanini G, Mussi A, et al. Tumor angiogenesis and biologic markers in resected stage I NSCLC. Eur J Cardiothorac Surg 1997;12:535–41.
Duarte IG, Bufkin BL, Pennington MF, et al. Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer. J Thorac Cardiovasc Surg 1998;115:652–9.
Apolinario RM, van der Valk P, de Jong JS, et al. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small cell lung cancer. J Clin Oncol 1997;15:2456–66.
Tanaka F, Yanagohara K, Otake Y, et al. Prognostic factors in patients with resected pathologic (p-) T1-2N1M0 non-small cell lung cancer (NSCLC). Eur J Cardiothorac Surg 2001;19:555–61.
Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 2000;18:2981–9.
Kalff V, Hicks RJ, MacManus MP, et al. Clinical impact of 18F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol 2000;19:111–8.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tanaka, F., Yanagihara, K., Otake, Y. et al. Prognostic Factors in Resected Pathologic (p-) Stage IIIA-N2, Non-Small-Cell Lung Cancer. Ann Surg Oncol 11, 612–618 (2004). https://doi.org/10.1245/ASO.2004.07.013
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1245/ASO.2004.07.013